Methylation Breakthrough: Advancing Cell-of-Origin Detection for Precision Medicine

Early and precise detection of neurological diseases, particularly Alzheimer’s, remains one of the biggest challenges in modern medicine. While liquid biopsy tools hold promise, current technologies lack the sensitivity and specificity needed for widespread clinical application. Could methylation-based cell-of-origin identification be the key to unlocking earlier, more accurate disease detection?

Join us for this expert-led webinar featuring a top neurologist and industry leaders from Wasatch BioLabs as we explore the clinical utility of methylation profiling, its challenges, and how emerging technologies are reshaping the landscape of neurological disease detection and monitoring.

What will you learn about:

• Clinical Perspective on Neurodegenerative Disease Testing - Dr. Burns will provide insights into the current state of clinical testing for neurological diseases such as Alzheimer’s. He will discuss the limitations of existing liquid biopsy tools and the urgent need for more advanced, reliable detection methods.
• Unlocking Methylation’s Potential - Tim Jenkins, PhD will introduce the power of methylation profiling with cell-of-origin identification, highlighting why this approach has remained underutilized in clinical applications. They will also present two groundbreaking case studies—ResonantDx and NOA Guide—demonstrating how new methylation technology is bridging this critical gap.
• Fireside Chat: The Future of Methylation in Neurology (Discussion) - Our experts will dive into: The challenges of early Alzheimer’s detection and why liquid biopsy advancements are crucial.

Who should attend:

• Neurologists & Neuroscientists
• Clinical Laboratory Directors & Pathologists
• Biotech & Pharma R&D Scientists
• Molecular & Epigenetics Researchers
• Oncologists & Cancer Researchers
• Translational Medicine Experts
• Hospital & Clinical Research Administrators